FOR IMMEDIATE RELEASE

Media contact: Shelli Lissick
shelli@bellmontpartners.com
651-276-6922

New Inspire Upper Airway Stimulation Therapy 18-Month Durability Research Shows Sustained Reductions in Obstructive Sleep Apnea (OSA) Severity, Improvement in Quality of Life

Data to Be Featured in Peer-Reviewed Publication and in Several Scientific Presentations at SLEEP 2015 in Seattle June 6 - 10

MINNEAPOLIS (June 4, 2015) — Inspire Medical Systems announced today that the manuscript entitled, *"Upper Airway Stimulation for Obstructive Sleep Apnea: Durability of the Treatment Effect at 18 months"* has been accepted for publication in SLEEP, the official journal of the American Academy of Sleep Medicine www.journalsleep.org

The Inspire Upper Airway Stimulation (UAS) therapy durability data demonstrates that significant reductions in obstructive sleep apnea (OSA) severity and quality of life measures were maintained at the 18-month mark. The outcomes data from the 22 center Stimulation Therapy for Apnea Reduction (STAR) Trial cohort demonstrates:

- A 67.4 percent reduction of apnea-hypopnea index (AHI) at 18 months.
- Quality of life measures including daytime sleepiness and functioning showed clinically meaningful and significant improvement over baseline.

Inspire therapy is an FDA-approved treatment for people with moderate to severe OSA who are unable to use or don't get relief from Continuous Positive Airway Pressure (CPAP). In contrast to CPAP, Inspire therapy works inside the body and with a patient's natural breathing process. The system includes a small neurostimulator, a sensing lead and a stimulation lead. The device is turned on with a handheld Inspire sleep remote and, when activated, Inspire therapy senses breathing patterns and delivers mild stimulation to key airway muscles which keeps the airway open during sleep.

"The clinical evidence supporting the use of Inspire therapy is very strong. With the publication of the 18-month durability data, there are now nine peer-reviewed

publications covering the safety, effectiveness and durability of Inspire therapy," says Tim Herbert, CEO of Inspire Medical Systems. "We also expect publication of the two-year and three-year outcomes data in the second half of 2015."

In addition, two-year and three-year objective and subjective outcomes data from the STAR Trial will be featured during several scientific sessions at the American Academy of Sleep Medicine (AASM)'s SLEEP 2015 meeting in Seattle, June 6-10, 2015. SLEEP attendees can learn more about Inspire therapy and the recent research results during the following conference presentations in Seattle:

- Tuesday, June 9th:
  - S09: *"Randomized Trials of Surgery for OSA"*
    - Room 6C; 10:20 am – 12:20 pm
  - O19: *"Obstructive Sleep Apnea Treatment"*
    - Room 6B; 4:30 pm – 4:45 pm
- Wednesday, June 10th:
  - D04: *"How Do New Clinical and Consumer-Oriented Tools Fit Within the Practice of Sleep Medicine?"*
    - Room 6B: 8:00 am – 10:00 am

Physicians attending the SLEEP conference and interested in learning more can also visit Inspire Medical Systems at booth #620.

STAR Trial 12-month data was first published in the January 9, 2014, edition of the *New England Journal of Medicine.*

About Inspire Therapy

Inspire Upper Airway Stimulation (UAS) is an FDA-approved treatment for people with moderate to severe OSA who are unable to use or don't get relief from CPAP. In contrast to CPAP, Inspire therapy works inside the body and with a patient's natural breathing process. The system includes a small neurostimulator, a sensing lead and a stimulation lead. The device is turned on with a handheld Inspire sleep remote and, when activated, Inspire therapy senses breathing patterns and delivers mild stimulation to key airway muscles which keeps the airway open during sleep. Patients implanted with Inspire therapy who participated in the Stimulation Therapy for Apnea Reduction (STAR) pivotal clinical trial experienced a 68 percent reduction in apnea events, a 70 percent reduction in oxygen desaturation events, and significant improvements in quality of life. These results were published in the January 9, 2014, issue of the *New England Journal of Medicine*. For more information, visit: www.inspiresleep.com

About Inspire Medical Systems

Inspire Medical Systems, based in Minneapolis, Minn., was incorporated in 2007 and has developed the world's first implantable FDA-approved neurostimulation system for the treatment of OSA. Privately held, investors include Aperture Venture

Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.